Dextrothyroxine

Dextrothyroxine (trade name Choloxin) saw research as a cholesterol-lowering drug[1][2] but was pulled due to cardiac side-effects. It also increases hepatic lipase which in turn improves utilization of triglycerides, improving apolipoprotein E cholesterol particles.

Dextrothyroxine
Clinical data
Trade namesCholoxin
Other namesD-3,5,3',5'-tetraiodothyronine
AHFS/Drugs.comMultum Consumer Information
Pregnancy
category
  • US: B (No risk in non-human studies)
    ATC code
    Legal status
    Legal status
    • Discontinued
    Identifiers
    CAS Number
    PubChem CID
    DrugBank
    ChemSpider
    UNII
    ChEBI
    ChEMBL
    CompTox Dashboard (EPA)
    ECHA InfoCard100.000.094
    Chemical and physical data
    FormulaC15H11I4NO4
    Molar mass776.87 g/mol g·mol−1
    3D model (JSmol)

    See also

    References

    1. Bantle, J. P.; Hunninghake, D. B.; Frantz, I. D.; Kuba, K.; Mariash, C. N.; Oppenheimer, J. H. (1984). "Comparison of effectiveness of thyrotropin-suppressive doses of D- and L-thyroxine in treatment of hypercholesterolemia". The American Journal of Medicine. 77 (3): 475–481. doi:10.1016/0002-9343(84)90107-4. PMID 6475988.
    2. Bommer, C.; Werle, E.; Walter-Sack, I.; Keller, C.; Gehlen, F.; Wanner, C.; Nauck, M.; März, W.; Wieland, H.; Bommer, J. (1998). "D-thyroxine reduces lipoprotein(a) serum concentration in dialysis patients". Journal of the American Society of Nephrology. 9 (1): 90–96. PMID 9440092.


    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.